Eribulin mesylate induces bone mass loss by promoting osteoclastic bone resorption in mice.

ABSTRACT: Over the past few decades, the clinical outcomes of patients with cancer have significantly improved mostly owing to the development of effective chemotherapeutic treatments. However, chronic health conditions such as bone mass loss and risk of fragility fractures caused by chemotherapy have also emerged as crucial issues in patients treated for cancer. In this study, we aimed to understand the effect of eribulin mesylate (ERI), a microtubule-targeting agent currently used to treat metastatic breast cancer and certain subtypes of advanced sarcomas, on bone metabolism in mice. The administration of ERI reduced bone mass in mice, mainly by promoting osteoclast activity. Gene expression analysis of skeletal tissues revealed no change in the expression levels of the transcripts for RANK ligand

SUBMITTER: Ishizaka T 

PROVIDER: S-EPMC10248043 | biostudies-literature | 2023 Jun

REPOSITORIES: biostudies-literature